Je was op zoek naar: approved rows (Deens - Fins)

rows( reference)
rows( viittaus)

applications to be placed on an approved list of suppliers .
applications to be placed on an approved list of suppliers .

rows( d2) giver 1
rows( d2) palauttaa arvon 1

rows( a1: c3) giver 3
rows( a1: c3) palauttaa arvon 3

vis sideopsætningnote: use multiple rows if needed
näytä sivun asetuksetnote: use multiple rows if needed

approved prescription services ltd 41 brampton road hampden park, eastbourne east sussex, bn22 9ag, det forenede kongerige
approved prescription services

eksportér til fil som datatabelnote: use multiple rows if needed
vie & tiedostoon tauluna... note: use multiple rows if needed

funktionen rows () giver antallet af rækker i en reference.
rows- funktio palauttaa viittauksen rivien lukumäärän.

concept paper on the development of an appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia
concept paper on the development of an appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia

( please specify each revenue budget line involved , adding the appropriate number of rows to the table where there is an effect on more than one budget line .
( please specify each revenue budget line involved , adding the appropriate number of rows to the table where there is an effect on more than one budget line .

adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow- acting anti- rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti- fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow- acting anti- rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti- fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications: